The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody

Journal of the American Academy of Dermatology

Volumn 45, Issue 5, 2001, Pages 665-674

  Papp, Kim ^a   Bissonnette, Robert ^b   Krueger, James G ^c   Carey, Wayne ^d   Gratton, David ^e   Gulliver, Wayne P ^f   Lui, Harvey ^g   Lynde, Charles W ^h   Magee, Anna ⁱ   Minier, Daniel ^j   Ouellet, Jean P ^j   Patel, Piyush ^k   Shapiro, Jerry ^g   Shear, Neil H ^l   Kramer, Susan ^m   Walicke, Patricia ^m   Bauer, Robert ⁿ   Dedrick, Russell L ⁿ   Kim, Sun Sook ⁿ   White, Mark ⁿ   Garovoy, Marvin R ⁿ   more..

^a PROBITY MEDICAL RESEARCH   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c ROCKEFELLER UNIVERSITY   (United States)

^d ROYAL VICTORIA HOSPITAL   (Canada)

^e MONTREAL GENERAL HOSPITAL   (Canada)

^f Newlab Clinical Research   (United States)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h Lynde Centre for Dermatology Canada   (Canada)

ⁱ CGA Clinical Research Center   (United States)

^j QandT Research   (Canada)

^k Allied Clinical Research   (Canada)

^l SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^m GENENTECH INC   (United States)

ⁿ XOMA (US) LLC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD11 ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD11A; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHENIA; BODY SURFACE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; PUVA; RANDOMIZED CONTROLLED TRIAL; URINARY TRACT DISEASE; VERTIGO; VOMITING;

EID: 17944381053     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2001.117850     Document Type: Article

References (29)

1. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment
2. Effectiveness of topical therapy for psoriasis: Results of a national survey
3. Treatment of psoriasis
4. An overview of psoriasis
5. Immunotherapy of psoriasis
6. Immunopathogenesis and immunotherapy of psoriasis
7. CTLA4lg-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
8. Novel approaches for the treatment of psoriasis
9. A multiple dose randomized double-blind placebo-controlled study to determine the efficacy and safety of a humanized anti-CD4 monoclonal antibody in the treatment of moderate to severe chronic psoriasis vulgaris
10. Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease
11. Anti-CD4 monoclonal antibody therapy in severe psoriasis
12. Interleukin 10 treatment of psoriasis: Clinical results of a phase 2 trial
13. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions
14. Role of lymphocyte adhesion receptors in transient interactions and cell locomotion
15. Adhesion receptors of the immune system
16. Role of the LFA-1 molecule in cellular interactions required for antibody production in humans
17. The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: Cell surface antigens associated with CTL-target interactions
18. Leukocyte membrane adhesion proteins LFA-1, CR3 and p150,95: A review of functional and regulatory aspects
19. The role of the LFA-1/ICAM-1 interaction in human leukocyte homing and adhesion
20. Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells
21. Humanization of an anti-lymphocyte function-associated antigen (LFA-1) monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1
22. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis
23. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis
24. Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?
25. Severe psoriasis: Oral therapy with a new retinoid
26. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B
27. Short-contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: A clinical and pathologic study
28. 389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
29. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients